MA34527B1 - Anticorps contre la metalloproteinase de matrice 9 - Google Patents
Anticorps contre la metalloproteinase de matrice 9Info
- Publication number
- MA34527B1 MA34527B1 MA35741A MA35741A MA34527B1 MA 34527 B1 MA34527 B1 MA 34527B1 MA 35741 A MA35741 A MA 35741A MA 35741 A MA35741 A MA 35741A MA 34527 B1 MA34527 B1 MA 34527B1
- Authority
- MA
- Morocco
- Prior art keywords
- matrix
- antibodies against
- mmp9
- functional fragment
- metalloproteinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des compositions et des procédés d'utilisation mettant en Suvre des protéines de liaison, par exemple, des anticorps et des fragments de liaison d'antigène de ceux-ci, qui se lient à la protéine de métalloprotéinase de matrice 9 (MMP9) (MMP9 est également appelée gélatinase B), les protéines de liaison comprenant une chaîne lourde d'immunoglobuline (Ig) (ou un fragment fonctionnel de celle-ci) et une chaîne légère de Ig (ou un fragment fonctionnel de celle-ci).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37788610P | 2010-08-27 | 2010-08-27 | |
PCT/US2011/049448 WO2012027721A2 (fr) | 2010-08-27 | 2011-08-26 | Anticorps contre la métalloprotéinase de matrice 9 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34527B1 true MA34527B1 (fr) | 2013-09-02 |
Family
ID=45724100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35741A MA34527B1 (fr) | 2010-08-27 | 2011-08-26 | Anticorps contre la metalloproteinase de matrice 9 |
Country Status (30)
Country | Link |
---|---|
US (7) | US8377443B2 (fr) |
EP (1) | EP2608809B1 (fr) |
JP (3) | JP5878538B2 (fr) |
KR (4) | KR101518144B1 (fr) |
CN (2) | CN103140240B (fr) |
AP (2) | AP2016009448A0 (fr) |
AU (1) | AU2011293125B2 (fr) |
BR (1) | BR112013004579B1 (fr) |
CA (1) | CA2808418C (fr) |
CL (1) | CL2013000535A1 (fr) |
CO (1) | CO6680656A2 (fr) |
CR (1) | CR20130132A (fr) |
EA (1) | EA031729B1 (fr) |
EC (1) | ECSP13012525A (fr) |
ES (1) | ES2739505T3 (fr) |
HK (1) | HK1208688A1 (fr) |
IL (2) | IL224614A (fr) |
MA (1) | MA34527B1 (fr) |
MX (1) | MX342413B (fr) |
NZ (2) | NZ701444A (fr) |
PE (1) | PE20131376A1 (fr) |
PH (1) | PH12016501691A1 (fr) |
PL (1) | PL2608809T3 (fr) |
PT (1) | PT2608809T (fr) |
SG (2) | SG188224A1 (fr) |
SI (1) | SI2608809T1 (fr) |
TR (1) | TR201910348T4 (fr) |
UA (1) | UA109908C2 (fr) |
WO (1) | WO2012027721A2 (fr) |
ZA (2) | ZA201301338B (fr) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101518144B1 (ko) | 2010-08-27 | 2015-05-28 | 길리아드 바이오로직스, 인크. | 매트릭스 메탈로프로테이나제 9에 대한 항체 |
ES2634098T3 (es) | 2011-01-14 | 2017-09-26 | The Regents Of The University Of California | Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos. |
SG11201405305PA (en) * | 2012-02-29 | 2014-09-26 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
NZ629178A (en) * | 2012-02-29 | 2016-09-30 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
AU2014248002A1 (en) * | 2013-04-05 | 2015-11-19 | Gregg B. Fields | Matrix metalloproteinases and uses thereof |
WO2015081127A2 (fr) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies pour le traitement de troubles myeloproliferatifs |
WO2015109286A1 (fr) | 2014-01-20 | 2015-07-23 | Gilead Sciences, Inc. | Thérapies pour le traitement de cancers |
EP2985296A1 (fr) * | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Anticorps spécifiques de MMP9 |
EP2985295A1 (fr) * | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Anticorps spécifiques de MMP9 |
TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
HUE050029T2 (hu) | 2015-03-04 | 2020-11-30 | Gilead Sciences Inc | 4,6-Diamino-pirido[3,2-d]pirimidin-származékok és alkalmazásuk toll-szerû receptorok modulátoraként |
CN105037553B (zh) * | 2015-08-20 | 2018-04-17 | 内蒙古蒙元生物基因科技有限公司 | 一种能够检测癌症的免疫球蛋白 |
JP2018530550A (ja) | 2015-10-01 | 2018-10-18 | ギリアド サイエンシズ, インコーポレイテッド | 癌を治療するためのbtk阻害剤とチェックポイント阻害剤との組合せ |
US20170174788A1 (en) * | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders |
US10316049B2 (en) | 2015-12-17 | 2019-06-11 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
CA3016081A1 (fr) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions et combinaisons d'inhibiteurs de l'autotaxine |
WO2017177179A1 (fr) | 2016-04-08 | 2017-10-12 | Gilead Sciences, Inc. | Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes |
CA3027209C (fr) | 2016-06-13 | 2022-08-16 | I-Mab | Anticorps anti-pd-l1 et leurs utilisations |
AU2017305303B2 (en) | 2016-08-04 | 2020-05-28 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
WO2018045150A1 (fr) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Dérivés de 4,6-diamino-pyrido [3,2-d] pyrimidine en tant que modulateurs du récepteur de type toll |
JP6746776B2 (ja) | 2016-09-02 | 2020-08-26 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体調節剤化合物 |
US20180133212A1 (en) | 2016-11-03 | 2018-05-17 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
US20180141939A1 (en) | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
CN110312737A (zh) | 2016-12-16 | 2019-10-08 | 波尔多大学 | Mmp9抑制剂及其在预防或治疗色素脱失病症中的用途 |
UA126571C2 (uk) | 2017-01-24 | 2022-11-02 | Ай-Маб Байофарма Юес Лімітед | Антитіло до cd73 та його застосування |
AR110998A1 (es) | 2017-02-24 | 2019-05-22 | Gilead Sciences Inc | Inhibidores de la tirosina cinasa de bruton |
JP2020508326A (ja) | 2017-02-24 | 2020-03-19 | ギリアド サイエンシズ, インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
WO2018170488A1 (fr) | 2017-03-17 | 2018-09-20 | Gilead Sciences, Inc. | Procédé de purification d'un anticorps |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
EP3656861A4 (fr) | 2017-07-18 | 2021-04-07 | Daiichi Sankyo Company, Limited | Peptide se liant à la mmp9 sous sa forme active |
EP3728283B1 (fr) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
CA3093888A1 (fr) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucleotides 3'3'-cycliques |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
WO2019211799A1 (fr) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle |
WO2019217780A1 (fr) | 2018-05-11 | 2019-11-14 | Phosphorex, Inc. | Microparticules et nanoparticules ayant des charges de surface négatives |
WO2019222112A1 (fr) | 2018-05-14 | 2019-11-21 | Gilead Sciences, Inc. | Inhibiteurs de mcl-1 |
CN112399874B (zh) | 2018-07-13 | 2024-03-22 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
EP3860717A1 (fr) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Dérivés d'imidozopyrimidine |
CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
IL282535B2 (en) | 2018-10-31 | 2024-05-01 | Gilead Sciences Inc | Transformed 6-azabanzimidazole compounds as HPK1 inhibitors |
CA3116347A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composes 6-azabenzimidazole substitues ayant une activite inhibitrice de hpk1 |
CN113574063A (zh) | 2019-03-07 | 2021-10-29 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
EP3935065A1 (fr) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
KR20210137517A (ko) | 2019-03-07 | 2021-11-17 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
JP7371243B2 (ja) | 2019-10-18 | 2023-10-30 | フォーティ セブン, インコーポレイテッド | 骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
CA3169451A1 (fr) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Anticorps et proteines de fusion se liant a ccr8, et leurs utilisations |
EP4143194A1 (fr) | 2020-05-01 | 2023-03-08 | Gilead Sciences, Inc. | Composés de 2,4-dioxopyrimidine inhibant cd73 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
WO2022271677A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
WO2023278491A1 (fr) * | 2021-06-28 | 2023-01-05 | Releviate, Llc | Anticorps anti-mmp-9 et leurs utilisations |
TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—3(2h)—酮衍生物 |
AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023107956A1 (fr) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Protéines se liant à nkg2d, cd16 et 5t4 |
WO2023107954A1 (fr) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Anticorps ciblant 5t4 et leurs utilisations |
WO2023122581A2 (fr) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
EP4245756A1 (fr) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Agents de dégradation de la famille des doigts de zinc de l'ikaros et leurs utilisations |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (fr) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Composés cd73 |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
CA2089661C (fr) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Animaux transgeniques non humains capables de produire des anticorps heterologues |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
CA2122732C (fr) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Proteines multivalentes fixatrices d'antigenes |
DE69412466T2 (de) | 1993-11-30 | 1999-04-29 | Fuji Yakuhin Kogyo Kk | Neue metalloprotease und kodierende dna dafür |
US5612030A (en) * | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
AU770718B2 (en) * | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
CA2379373A1 (fr) | 1999-07-13 | 2001-01-18 | University Of Southern California | Nouvelles methode et composition d'inhibition de l'angiogenese utilisant des antagonistes bases sur les integrines mmp-9 et .beta.1 |
US7101975B1 (en) | 1999-07-13 | 2006-09-05 | University Of Southern California | Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins |
WO2002066057A2 (fr) | 2001-02-23 | 2002-08-29 | Biophage Inc. | Methodes et compositions de prevention et de traitement de maladies induites par les neutrophiles |
SE0102298D0 (sv) | 2001-06-27 | 2001-06-27 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
WO2003006006A1 (fr) | 2001-07-09 | 2003-01-23 | The Regents Of The University Of California | Utilisation d'inhibiteurs de metalloproteinases matricielles pour limiter les atteintes nerveuses |
WO2003044058A2 (fr) | 2001-11-23 | 2003-05-30 | Universite Catholique De Louvain | Utilisation medicale d'anticorps diriges contre des metalloproteinases matricielles humaines ou des proteinases tissulaires associees, aux fins de traitement de saignements uterins anomaux et d'endometriose |
AU2003270330B2 (en) | 2002-09-06 | 2009-07-30 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component C5 |
WO2004076614A2 (fr) | 2003-02-27 | 2004-09-10 | Bernd Hinzmann | Sequences d'acide nucleique humaines issues de carcinomes de la prostate |
US7524938B2 (en) * | 2003-04-04 | 2009-04-28 | Yeda Research And Development Co., Ltd. | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
WO2006037513A1 (fr) | 2004-10-09 | 2006-04-13 | Bayer Healthcare Ag | Agents diagnostiques et agents therapeutiques utilises dans le cadre de maladies associees a la metalloproteinase 9 matricielle (mmp9) |
US20070003981A1 (en) | 2005-06-29 | 2007-01-04 | Rules-Based Medicine, Inc. | Methods and kits for the diagnosis of acute coronary syndrome |
US8957187B2 (en) | 2005-12-02 | 2015-02-17 | Genentech, Inc. | Binding polypeptides and uses thereof |
WO2007144781A2 (fr) | 2006-04-21 | 2007-12-21 | Diagnotech Pty. Ltd. | Procédés de diagnostic et trousses utilisant des anticorps dirigés contre des métalloprotéases |
WO2008088864A2 (fr) | 2007-01-18 | 2008-07-24 | The Trustess Of Columbia University In The City Of New York | Procédés associés à une métalloprotéinase-9 matricielle |
JP5513130B2 (ja) * | 2007-02-23 | 2014-06-04 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 金属タンパク質の活性を阻害するために有用な抗体および該抗体を含有する医薬組成物 |
AR066913A1 (es) | 2007-06-08 | 2009-09-23 | Irm Llc | Metodos y composiciones para inducir la apoptosis en celulas cancerosas |
CN102083455B (zh) | 2007-08-15 | 2015-01-07 | 耶达研究及发展有限公司 | Mmp-9的调节剂及其用途 |
CA2707637A1 (fr) | 2007-12-17 | 2009-06-25 | Dyax Corp. | Compositions et procedes pour traiter des troubles osteolytiques comprenant des proteines de liaison a mmp-14 |
CA2717576A1 (fr) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Proteines de liaison a la metalloproteinase 9 |
CA2717803A1 (fr) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Proteines de liaison a la metalloproteinase 9 et a la metalloproteinase 2 |
AU2009308369A1 (en) | 2008-10-22 | 2010-04-29 | Dyax Corp. | Combination treatments comprising protease binding proteins for inflammatory disorders |
WO2010059543A1 (fr) | 2008-11-20 | 2010-05-27 | Merck Sharp & Dohme Corp. | Génération et caractérisation d’anticorps anti-notch pour utilisation thérapeutique et diagnostique |
CN102822202B (zh) | 2010-01-27 | 2015-07-22 | 耶达研究及发展有限公司 | 抑制金属蛋白的抗体 |
US20110261695A1 (en) * | 2010-04-23 | 2011-10-27 | Xiaoming Zhao | System and method for network congestion control |
KR101518144B1 (ko) | 2010-08-27 | 2015-05-28 | 길리아드 바이오로직스, 인크. | 매트릭스 메탈로프로테이나제 9에 대한 항체 |
SG11201405305PA (en) | 2012-02-29 | 2014-09-26 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
NZ629178A (en) | 2012-02-29 | 2016-09-30 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
-
2011
- 2011-08-26 KR KR1020137007599A patent/KR101518144B1/ko active IP Right Grant
- 2011-08-26 NZ NZ701444A patent/NZ701444A/en not_active IP Right Cessation
- 2011-08-26 KR KR1020147035325A patent/KR101827048B1/ko active IP Right Grant
- 2011-08-26 TR TR2019/10348T patent/TR201910348T4/tr unknown
- 2011-08-26 PT PT11820759T patent/PT2608809T/pt unknown
- 2011-08-26 US US13/219,523 patent/US8377443B2/en active Active
- 2011-08-26 AU AU2011293125A patent/AU2011293125B2/en active Active
- 2011-08-26 MX MX2013002323A patent/MX342413B/es active IP Right Grant
- 2011-08-26 AP AP2016009448A patent/AP2016009448A0/en unknown
- 2011-08-26 PE PE2013000344A patent/PE20131376A1/es active IP Right Grant
- 2011-08-26 ES ES11820759T patent/ES2739505T3/es active Active
- 2011-08-26 JP JP2013526186A patent/JP5878538B2/ja active Active
- 2011-08-26 SI SI201131732T patent/SI2608809T1/sl unknown
- 2011-08-26 PL PL11820759T patent/PL2608809T3/pl unknown
- 2011-08-26 CN CN201180041422.8A patent/CN103140240B/zh active Active
- 2011-08-26 AP AP2013006743A patent/AP3948A/en active
- 2011-08-26 KR KR1020187002896A patent/KR101881724B1/ko active IP Right Grant
- 2011-08-26 UA UAA201302088A patent/UA109908C2/uk unknown
- 2011-08-26 BR BR112013004579-5A patent/BR112013004579B1/pt not_active IP Right Cessation
- 2011-08-26 MA MA35741A patent/MA34527B1/fr unknown
- 2011-08-26 EP EP11820759.6A patent/EP2608809B1/fr active Active
- 2011-08-26 EA EA201390146A patent/EA031729B1/ru not_active IP Right Cessation
- 2011-08-26 NZ NZ606880A patent/NZ606880A/en not_active IP Right Cessation
- 2011-08-26 WO PCT/US2011/049448 patent/WO2012027721A2/fr active Application Filing
- 2011-08-26 CN CN201410816632.5A patent/CN104530238B/zh active Active
- 2011-08-26 CA CA2808418A patent/CA2808418C/fr active Active
- 2011-08-26 KR KR1020177006624A patent/KR101930179B1/ko active IP Right Grant
- 2011-08-26 SG SG2013011341A patent/SG188224A1/en unknown
- 2011-08-26 SG SG10201506703VA patent/SG10201506703VA/en unknown
-
2012
- 2012-09-14 US US13/619,318 patent/US8501916B2/en active Active
-
2013
- 2013-02-07 IL IL224614A patent/IL224614A/en active IP Right Grant
- 2013-02-20 ZA ZA2013/01338A patent/ZA201301338B/en unknown
- 2013-02-22 CO CO13036730A patent/CO6680656A2/es unknown
- 2013-02-25 CL CL2013000535A patent/CL2013000535A1/es unknown
- 2013-03-21 CR CR20130132A patent/CR20130132A/es unknown
- 2013-03-25 EC ECSP13012525 patent/ECSP13012525A/es unknown
- 2013-07-03 US US13/935,370 patent/US9120863B2/en active Active
- 2013-07-03 US US13/935,352 patent/US9260532B2/en active Active
-
2015
- 2015-08-28 US US14/839,503 patent/US20160159923A1/en not_active Abandoned
- 2015-09-24 HK HK15109390.0A patent/HK1208688A1/xx unknown
- 2015-09-25 ZA ZA2015/07081A patent/ZA201507081B/en unknown
- 2015-10-23 JP JP2015208653A patent/JP6198797B2/ja active Active
-
2016
- 2016-01-11 US US14/992,678 patent/US20160122437A1/en not_active Abandoned
- 2016-08-25 PH PH12016501691A patent/PH12016501691A1/en unknown
-
2017
- 2017-08-22 JP JP2017159712A patent/JP6435381B2/ja active Active
- 2017-09-05 US US15/695,765 patent/US20180086845A1/en not_active Abandoned
- 2017-10-29 IL IL255300A patent/IL255300A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34527B1 (fr) | Anticorps contre la metalloproteinase de matrice 9 | |
CY1124802T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
MA40801A1 (fr) | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 | |
EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
CY1120951T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
MA30353B1 (fr) | Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes. | |
MA33387B1 (fr) | Polypeptides et procede de traitement | |
MA35740B1 (fr) | Compositions et procédés pour des anticorps ciblant le facteur p | |
TNSN07398A1 (fr) | Anticorps contre la p-cadherine | |
MA35345B1 (fr) | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn | |
MA33757B1 (fr) | Protéines de liaison à l'antigène de l'il-23 humaine | |
MA35174B1 (fr) | Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines | |
CY1110792T1 (el) | Αντισωματα αντι-ιl-23 | |
EA200702361A1 (ru) | АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ | |
BR112021023540A2 (pt) | Agentes de afinidade | |
MY149858A (en) | Rodent pest control | |
EA201691414A1 (ru) | Антитела к матриксной металлопротеиназе 9 и способы их применения | |
MA47976B1 (fr) | Anticorps dirigés contre trem2 et leur utilisation | |
EA202193238A1 (ru) | Аффинные агенты к аав9 | |
MA52675A1 (fr) | Anticorps anti-staphylococcus et leurs utilisations | |
EA202191187A1 (ru) | Антитела к ctla4, фрагменты антител, их иммуноконъюгаты и их применение | |
MA50374A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA37523B1 (fr) | Protéines de liaison à l'antigène st2 |